Analysis of circulating tumor and cancer stem cells provides new opportunities in diagnosis and treatment of small cell lung cancer

[thumbnail of Open Access]
Preview
Text (Open Access) - Published Version
· Available under License Creative Commons Attribution.
· Please see our End User Agreement before downloading.
| Preview
Available under license: Creative Commons Attribution
[thumbnail of ijms-1887826_with_supplementary_data.pdf]
Text - Accepted Version
· Restricted to Repository staff only
Restricted to Repository staff only

Please see our End User Agreement.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email

Skurikhin, E. G., Ermakova, N., Zhukova, M., Pershina, O., Pan, E., Pakhomova, A., Kogai, L., Goldberg, V., Simolina, E., Skurikhina, V., Widera, D. orcid id iconORCID: https://orcid.org/0000-0003-1686-130X, Kubatiev, A., Morozov, S. G., Kushlinskii, N. and Dygai, A. (2022) Analysis of circulating tumor and cancer stem cells provides new opportunities in diagnosis and treatment of small cell lung cancer. International Journal of Molecular Sciences, 23 (18). 10853. ISSN 1422-0067 doi: 10.3390/ijms231810853

Abstract/Summary

Current methods for diagnosis and treatment of small cell lung cancer (SCLC) have only modest efficacy. In this pilot study, we analysed circulating tumour cells (CTCs) and cancer stem cells (CSCs) in patients with SCLC to search for new diagnostic and prognostic markers and novel approaches to improve the treatment of the disease. In other forms of lung cancer, we have shown a heterogeneity of blood CTCs and CSCs populations, as well as changes in other cell populations (ALDH+, CD87+CD276+ and EGF+Axl‒) in smokers. A number of CTCs and CSCs in patients with SCLC have been shown to be resistant to chemotherapy (CT). High cytotoxic activity and resistance to apoptosis of reprogrammed CD3+CD8+ T-lymphocytes (rTcells) in relation to naive CD3+CD8+ T- lymphocytes was demonstrated in a smoking patient with SCLC (Patient G) in vitro. The target for rTcells was patient G's blood CSCs. Reprogramming of CD3+CD8+ T-lymphocytes was carried out with the MEK1/2 inhibitor and PD-1/PD-L1 pathway blocker nivolumab. The training procedure was performed with a suspension of dead CTCs and CSCs obtained from patient`s G blood. The presented data show a new avenue for personalized SCLC diagnosis and targeted improvement of chemotherapy based on the use of both CTCs and CSCs.

Altmetric Badge

Item Type Article
URI https://reading-clone.eprints-hosting.org/id/eprint/107307
Identification Number/DOI 10.3390/ijms231810853
Refereed Yes
Divisions Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Division of Pharmacology
Publisher MDPI
Download/View statistics View download statistics for this item

Downloads

Downloads per month over past year

University Staff: Request a correction | Centaur Editors: Update this record

Search Google Scholar